HTL 18318

Drug Profile

HTL 18318

Alternative Names: HTL 0018318; HTL18318

Latest Information Update: 09 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Heptares Therapeutics
  • Developer Allergan; Heptares Therapeutics
  • Class Antidementias; Antipsychotics; Nootropics; Small molecules
  • Mechanism of Action Muscarinic M1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Alzheimer's disease; Cognition disorders

Most Recent Events

  • 10 Nov 2017 Phase-Ib clinical trials in Alzheimer's disease (Adjunctive therapy, In adults, In the elderly) in Spain, Slovakia, Poland, Czech Republic (unspecified route) (NCT03456349)
  • 09 Nov 2017 Sosei Group Corporation plans a phase II proof-of-concept study of HTL 18318 for Dementia with Lewy bodies (Monotherapy) in Japan in 2018 (Trial profile 700267790)
  • 20 Aug 2017 Heptares Therapeutics completes a phase I trial in Healthy volunteers in United Kingdom (PO) (NCT03198624)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top